American Association for Cancer Research

Skip to Main Content

Table 3.

Relative expression of NER proteins in SCCHN patients and controls

	n*	Mean ± SD			Difference (%)	P^†
	n*			Cases	Difference (%)	P^†	Controls
Age (y)	57/63	56.2 ± 9.7	57.2 ± 9.5		0.418
Storage time	57/63	17.7 ± 11.7	13.2 ± 6.8		0.013
Relative expression (%)^‡
ERCC1	53/58	1.369 ± 0.401	1.696 ± 0.539	−19.3	<0.001
XPA	53/61	0.363 ± 0.111	0.424 ± 0.160	−14.4	0.017
XPC	54/62	1.326 ± 0.650	1.770 ± 0.923	−25.1	0.003
XPD	52/59	0.947 ± 0.343	1.137 ± 0.584	−19.0	0.037
XPF	56/62	0.966 ± 0.438	1.297 ± 0.764	−25.5	0.004
XPG	55/60	1.206 ± 0.453	1.432 ± 0.628	−15.8	0.028

	n*	Mean ± SD			Difference (%)	P^†
	n*			Cases	Difference (%)	P^†	Controls
Age (y)	57/63	56.2 ± 9.7	57.2 ± 9.5		0.418
Storage time	57/63	17.7 ± 11.7	13.2 ± 6.8		0.013
Relative expression (%)^‡
ERCC1	53/58	1.369 ± 0.401	1.696 ± 0.539	−19.3	<0.001
XPA	53/61	0.363 ± 0.111	0.424 ± 0.160	−14.4	0.017
XPC	54/62	1.326 ± 0.650	1.770 ± 0.923	−25.1	0.003
XPD	52/59	0.947 ± 0.343	1.137 ± 0.584	−19.0	0.037
XPF	56/62	0.966 ± 0.438	1.297 ± 0.764	−25.5	0.004
XPG	55/60	1.206 ± 0.453	1.432 ± 0.628	−15.8	0.028

Number of cases/controls.

Calculated using two-sided Student's t test.

Expression level relative to that of β-actin.